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Abstract
FKBP51 and FKBP52 are diverse regulators of steroid hormone receptor signaling including
regulation of receptor maturation, hormone binding, and nuclear translocation. Although
structurally similar, they are functionally divergent, which is largely attributed to differences in the
FK1 domain and the proline-rich loop. FKBP51 and FKBP52 have emerged as likely contributors
to a variety of hormone-dependent diseases including stress-related diseases, immune function,
reproductive functions and a variety of cancers. In addition, recent studies have implicated
FKBP51 and FKBP52 in Alzheimer’s disease and other protein aggregation disorders. This review
summarizes our current understanding of FKBP51 and FKBP52 interactions within the receptor-
chaperone complex, their contributions to health and disease, and their potential as therapeutic
targets for the treatment of these diseases.
FKBP51 and FKBP52 Structure and Function
It has been 20 years since the 51 and 52-kDa FK506 binding proteins FKBP51 and FKBP52
were first identified in complex with the steroid hormone receptors [1, 2]. Since that time,
much progress has been made in understanding the mechanisms by which they regulate
steroid hormone receptor signaling, and the resulting roles they play in endocrine-related
physiological processes. Over the years, FKBP51 and FKBP52 have emerged as potential
therapeutic targets for a wide variety of endocrine-related diseases including prostate cancer,
breast cancer, male and female contraception, stress-related diseases, and metabolic
diseases. As a result, researchers in academia and industry are increasingly focused on the
identification and development of novel drugs that target FKBP51 and FKBP52.
FKBP51 and FKBP52 are Hsp90 co-chaperones that modify steroid hormone receptor
(SHR) activity. FKBP51 and FKBP52 share 70% similarity and contain an active peptidyl
prolyl isomerase (PPIase) domain, bind the 90-kDa heat shock protein (Hsp90) through a C-
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terminal tetratricopeptide repeat (TPR) domain [3], and adopt similar conformations (Figure
1) [reviewed in 4]. FKBP52 is a positive regulator of glucocorticoid receptor (GR) [5],
progesterone receptor (PR) [6], and androgen receptor (AR) [7], but not estrogen receptor
(ER) or mineralocorticoid receptor (MR) [5]. FKBP51 is a negative regulator of SHR
activity in most studies reported [reviewed in 8]. The FKBPs compete for binding to the
SHR complex and, as a result, overexpression of FKBP51 decreases receptor regulation by
FKBP52 [5] and in the case of AR, hormone binding affinity is increased five-fold in the
presence of FKBP52 versus FKBP51 [9].
The major FKBP functional domains include the FKBP12-like domains 1 and 2 (FK1 and
FK2) and the tetratricopeptide repeat (TPR) domain (Figure 1) [10]. The FK1 domain
facilitates binding to the immunosuppressive drug FK506, confers PPIase activity [3], and is
the primary regulatory domain for SHRs [5]. FKBP51 and FKBP52’s FK1 domains exhibit
comparable PPIase enzymatic activity towards small peptide substrates. The FK1 domain is
deemed critical for receptor potentiation by FKBP52 [5], but its enzymatic activity is not
required for this potentiation. Domain integrity in and around the PPIase pocket is essential
[9]. Although residues critical for PPIase activity are conserved in FKBP52 and FKBP51,
residues of the proline-rich loop, suspended above the PPIase pocket, differ, thus
significantly affecting protein interactions with larger peptide substrates [3, 10]. These
differences are also likely responsible for the divergent functions of the FKBPs, as a
randomly identified FKBP51 mutant containing two point mutations (A116V and L119P) in
the FKBP51 proline-rich loop gained full FKBP52-like activity towards AR [9].
Seven to nine amino acids of the FK linker connect the FK1 and FK2 domains in FKBP51
and FKBP52. In FKBP52, this linker is crowned by the Casein Kinase 2 (CK2)
phosphorylation sequence TEEED. CK2 phosphorylation at T143 could decrease binding to
Hsp90 [11], but this finding was not replicated in an in vitro study in which a direct
comparison of Hsp90 binding was compared between wild type FKBP52 and the
phosphomimetic mutant FKBP52-T143E [12]. Phosphorylation of T143 completely
abrogates FKBP52 regulation of receptor function and is predicted to reorient the
conformation of the FK1 domain. In FKBP51, this loop is crowned by the sequence FED, so
phosphorylation of this site is not achieved. However, this difference does not account for
the lack of receptor potentiation ability of FKBP51.
The FK2 domain is still enigmatic; while structurally similar to FK1, it lacks PPIase activity
and does not bind the drug FK506. Deletion of three amino acids in the FKBP51 FK2
domain (D195, H196, and D197) does not disrupt Hsp90 binding, but the mutant does not
integrate normally into progesterone receptor complexes. [10]. It is possible that this
mutation decreases interaction with other components of the receptor complex, possibly
even the receptor itself.
The TPR domain confers Hsp90 binding ability to the FKBPs through interaction with the
EEVD motif in the extreme C-terminus of Hsp90. The TPR domain is characteristic of all
FKBPs, which interact with SHR complexes. Isothermal titration calorimetry suggests that
FKBP51’s PPIase domain binds an Hsp90 dimer with only 25 to 33% of the affinity of
FKBP52’s PPIase domain [3]. However, the FKBPs’ affinities for Hsp90 do not accurately
predict the abundance of FKBPs in Hsp90-mediated receptor complexes. In a reticulocyte
lysate assembly system, PR complexes showed a preference for FKBP51, GR complexes
preferred FKBP51 and Protein Phosphatase 5 (PP5), and ER complexes preferred
Cyclophilin 40 (Cyp40) [13]. The phenomenon of client specificity augments the possibility
that the FKBPs could potentiate receptors through direct association or through unique,
receptor-specific adapter proteins. Indeed, Hsp90-independent interactions have been
reported between GR and FKBP52’s FK1 domain [14].
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In this article we propose a model which holds that the FKBP52 FK1 domain, the proline-
rich loop in particular, is not only responsible for the divergent functions of the FKBPs, but
also serves as an interaction surface. The receptor specificity displayed by the FKBPs
suggests that they directly contact the receptors within the receptor-chaperone complex. The
fact that FKBP52 regulation has been localized to the receptor ligand binding domain (LBD)
[5, 15] suggests that the FK1 interaction partner is the receptor LBD. We propose that
interaction with Hsp90-receptor complex, which is stabilized by the p23 cochaperone, brings
the FKBP FK1 domain into contact with the receptor LBD, directly affecting the hormone
binding affinity of the receptor (Figure 2; Box 1). The FKBP interaction surface on the
receptor and the molecular mechanism by which this occurs is currently under investigation
(Box 3).
Roles for FKBP51 and FKBP52 in Receptor Localization
In the absence of ligand, some SHRs reside primarily in the cytoplasm whereas others are
nuclear. Regardless of their primary localization, these receptors are not confined to any
particular cell compartment and shuttle continuously between cytoplasm and nucleus [16,
17]. It has always been assumed that simple diffusion is the driving force of movement for
these signaling molecules. However, the observation that proteins of the dynein/dynactin
complex co-immunoprecipitate with the hsp90•FKBP52 complex and also with GR [18–20]
and MR [21–23], suggests that these motor proteins could power the retrograde movement
of these steroid receptors. Several observations agree with this hypothesis. The steroid-
dependent nuclear accumulation of primarily cytoplasmic steroid receptors is rapid (t0.5 = 4–
5 min), but treatment of cells with hsp90-disrupting agents such as geldanamycin, lowers the
rate of translocation by an order of magnitude (t0.5 = 40–60 min), during which the
hsp90•FKBP52 complex is inactivated [18, 21]. The rapid, hsp90•FKBP-dependent
movement of steroid receptors requires cytoskeletal tracts, tubulin being physically linked to
the receptor•hsp90•FKBP52•motor protein complex [17, 24]. Co-immunoprecipitation of
dynein and subunit components of dynactin with FKBP52 demonstrated that the motor
protein complex binds the N-terminus of FKBP52 in a manner that appears to be
independent of the PPIase activity of FKBP52 [23, 25]. Rather, the PPIase domain acts as a
protein-protein interaction domain and the association of dynein/dynactin with FKBP52 is
not affected by FK506.
Because the FKBPs and hsp90 are part of the same functional complex, it can be envisage
that the disruption of the interaction between the FKBPs and the motor proteins should yield
similar levels of inhibition of SHR retrotransport as that measured in the presence of hsp90
inhibitors. This was demonstrated when the receptor was “disconnected” from the transport
machinery by overexpression of the PPIase peptide (interferes with dynein binding to
FKBP52) [18–20], the TPR peptide (blocks FKBP52 binding to hsp90) [23] or the p50/
dynactin2 subunit of dynactin [18, 20]. On the other hand, nuclear translocation of GR is
delayed by FKBP51, which correlates with the poor interaction of FKBP51 with dynein
[20].
In all these cases, the nuclear localization of the cargo was not fully inhibited but simply
impaired, suggesting the existence of two types of transport, the rapid
hsp90•FKBP52•dynein/dynactin-dependent mechanism (t0.5 = 4–5 min), and an alternative,
heterocomplex-independent and less efficient mechanism (t0.5 = 40–60 min), which could be
due to simple diffusion. Importantly, when the nuclear translocation rate of these receptors
was impaired, they became highly sensitive to proteasomal degradation [26]. The same
heterocomplex described for steroid receptors is also responsible for the cytoplasmic
retrotransport of the proapototic factor p53 [27], suggesting that the hsp90-based complex
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may play a general role in the retrotransport of a number of hsp90-associated factors
towards the nuclear surface.
Inasmuch as the chaperone molecular bridge provides the traction chain for the nuclear
factor to be transported throughout the cytoplasm via microtubule tracks, the dissociation of
the hsp90-based complex from SHRs should not occur directly after ligand binding because
the hsp90•FKBP52 complex is required for the normal mechanism of retrotransport [28].
This is a major modification of the model postulated decades ago for SHR activation, which
sustained the principle that hsp90 “anchors” SHRs in the cytoplasmic compartment and only
the cytoplasmic dissociation of the chaperone permits the nuclear translocation of the
receptor [29, 30] (Figure 3; Box 1). The new model for SHR retrotransport implies that the
chaperone machinery should remain associated to the receptor. It also implies that it could
interact with structures of the nuclear pore complex during the nuclear translocation process.
Recently, it was demonstrated that the chaperone complex binds the integral nuclear pore
glycoprotein Nup62 and also β-importin [31]. This facilitates the passage of the
untransformed receptor through the channel of the nuclear pore. It is possible that the
chaperone complex associated to importins, nucleoporins, and the cargo itself can act as a
cooperative system to prevent the aggregation of cargoes when their hydrophobic domains
are exposed in the channel during the translocation step. The association of TPR proteins
such as FKBP52 to Nup62 is hsp90-dependent, as shown by the dissociation of FKBP52
from Nup62 with radicicol. Nonetheless, indirect immunofluorescence assays performed in
intact cells treated with radicicol still show the presence of FKBP52 in the perinuclear ring
[31], suggesting that this TPR protein may also bind in an hsp90-independent manner to
other perinuclear structures, for example other nucleoporins. Competition experiments by
overexpression of the TPR domain showed that the perinuclear signal of FKBP52 was
totally abolished, indicating that the TPR domain is required for most, if not all associations
of FKBP52 with any structure of the nuclear envelope [31].
FKBP51 and FKBP52 in Health and Disease
Reproductive Development and Success
A role for FKBP52 in mammalian reproductive development and success emerged from the
development and study of two independently derived fkbp52-deficient (52KO) mouse lines.
The phenotypes observed in these mice directly correlate with observations previously
obtained in biochemical and cellular studies. Male 52KO mice display phenotypes
consistent with partial androgen insensitivity including dysgenic prostate and seminal
vesicles, ambiguous external genitalia including hypospadias, and retention of nipples into
adulthood [7, 32]. Despite the androgen insensitivity, the testis of 52KO mice develop
normally. Whether some factor exists within the testis that can complement for the loss of
FKBP52, or the androgen levels produced locally within the testis are enough to compensate
for reduced AR activity, is currently unclear. 52KO male mice do have reduced epididymal
sperm counts and the sperm display abnormal morphology. FKBP52 was also reported to be
present in epididymal sperm flagella and 52KO animals display reduced sperm motility [33].
The androgen insensitivity observed in the 52KO mice does not account for reduced sperm
motility, as this is an androgen-independent process. As discussed above, FKBP52 does
interact with dynein motor proteins, suggesting a possible role for FKBP52 in the regulation
of flagella movement. The available evidence suggests that FKBP52 may serve as an
attractive target for male contraceptives; however, further studies into the role of FKBP52 in
the testis and in sperm maturation and motility are needed (Box 3).
Female 52KO mice appear morphologically normal and display normal ovulation and
fertilization; yet, they are infertile. The infertility is the result of embryonic implantation and
decidualization failure due to progesterone insensitivity and uterine defects [6, 34, 35].
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Implantation failure may be due to increased uterine oxidative stress, as 52KO animals were
sensitive to paraquat-induced oxidative stress, have reduced levels of the anti-oxidant
peroxiredoxin-6 (PRDX6) and addition of exogenous antioxidant rescued implantation [34,
36]. Finally, FKBP52 may promote endometriosis, as women with endometriosis show
reduced FKBP52 expression, and the progesterone resistance, observed in 52KO mice,
results in increased cell proliferation, inflammation, and angiogenesis, leading to
endometriotic lesions [37]. Thus, evidence suggests a critical role for FKBP52 in female
reproduction and uterine signaling.
The fkbp51-deficient (51KO) mice display no overt morphological phenotypes. However,
the loss of both FKBP51 and FKBP52 (51/52KO) proteins results in embryonic lethality,
although the cause of this phenotype has not been investigated (Box 3). Thus, FKBP51 and
FKBP52 have some redundant role(s) in embryonic development. Whether or not this is an
endocrine-related role is unknown and it could result from one or several of the non-
endocrine related functions that have recently been characterized for the FKBP proteins.
One of the more recent discoveries demonstrates a role of the FKBP proteins in microtubule
assembly and tau pathogenesis [38, 39] (Box 2). This is of particular interest, as it is the first
example of a PPIase-dependent function for FKBP51 and FKBP52.
Cell Proliferation and Cancer
Research on FKBP51 in cancer etiology and response to antineoplastic therapy has
intensified recently. Initially, FKBP51 was reported as an androgen-regulated gene in
prostate cancer and a modulator of androgen receptor (AR) activity [reviewed in 40]. The
protein is also upregulated in prostatic hyperplasia [41]. In prostate cancer cell lines,
increased levels of FKBP51 and FKBP52 were reported, as well as an inhibitory effect of
FK506 on androgen-stimulated cell growth [42]. While gene knock-out strategies revealed
FKBP52, but not FKBP51, as an important facilitator of physiological AR activity [7, 32],
FKBP51 was also identified as a positive regulator of AR and androgen-dependent cell
growth, and as a target of FK506 in prostate cancer cells [43, 44]. Potentiation of AR by
FKBP51 was not found in other studies and may be cell type dependent [9, 45].
In colorectal adenocarcinoma, FKBP51 suppresses proliferation, which was ascribed to its
action on GR [46]. GR action has also been invoked in myeloma cells, where
dexamethasone-induced expression of FKBP51 has been interpreted as an adaptive process
prior to cell death [47]. In leukemia, inhibiting FKBP51 by rapamycin abolished
doxorubicin-induced activation of NF-kB and thus enhanced drug-induced apoptosis [48]. A
recent study presented FKBP51 as a marker of melanocyte malignancy [49]. Irradiation
caused apoptosis in cells with silenced FKBP51 and promoted autophagy in control cells.
Inhibition of apoptosis in control cells involved FKBP51-dependent induction of NF-kB
upon irradiation.
A major advance in mechanistic understanding was the discovery that FKBP51 negatively
regulates the activity of the cell growth regulator Akt, by serving as a scaffolding protein to
recruit the phosphatase PHLPP [50]. FKBP51 expression is decreased in several cancer cell
lines and in pancreatic cancer tissue, and may correlate with increased Akt phosphorylation
and reduced cell sensitivity to chemotherapeutic agents.
Overall, it appears that depending on cell and cancer type, promoting or reducing FKBP51
activity can produce a beneficial effect in the actions against cancer cell proliferation. Most
likely this is due to the multitude of molecular functions of FKBP51, and this should be
carefully considered when developing FKBP51 targeting drugs for cancer therapy [49].
Most likely, FKBP51 uses at least partially different surfaces for its divergent actions, which
eventually could be exploited for specific drug development.
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Given that FKBP51 expression is hormone-regulated [reviewed in 8], altered FKBP51
expression has been associated with a wide variety of cancers. In contrast, FKBP52 is
ubiquitously expressed at high levels, and is slightly up-regulated under stress conditions
[1]. Thus, less is known on the role of FKBP52 in cancer. Given the androgen, progesterone
and glucocorticoid insensitivity phenotypes observed in the fkbp52-deficient mice [6, 7, 32,
35, 51], FKBP52 is likely to have an important role and to serve as a therapeutic target in a
variety of diseases that are dependent on these hormone signaling pathways.
The prostate dysgenesis observed in 52KO mice established FKBP52 as a critically
important regulator of prostate development [7], and enhanced FKBP52 levels have been
observed in prostate needle biopsies from human patients [52]. In addition, a series of
compounds that specifically inhibit FKBP52 regulation of androgen receptor function
effectively block androgen-dependent gene expression and cell proliferation in prostate
cancer cells [53]. Although FKBP52 is not a functional regulator of ER in cellular studies,
FKBP52 expression is up-regulated in breast tumors, and recent studies found FKBP52 gene
methylation in ER-negative, but not in ER-positive breast cancer cells [reviewed in 54].
Thus, FKBP52 may also have a role in breast cancer tumorigenesis and/or progression.
Stress-Related Diseases and Phenotypes
The search for molecular parameters in psychiatric disorders identified a correlation of an
imbalanced stress hormone system, the hypothalamus pituitary adrenal (HPA) axis, with the
risk for and course of diseases like major depression, bipolar disorder, post-traumatic stress
disorder (PTSD), schizophrenia and anxiety disorders [55, 56]. The HPA axis is a hormone
cascade comprising the corticotropin-releasing hormone (CRH) secreted upon stress, which
triggers synthesis and release of corticotropin, resulting in the secretion of cortisol that acts
on various tissues (Figure 4). A crucial characteristic of the HPA axis is the negative
feedback exerted by cortisol via the glucocorticoid receptor (GR) that keeps the stress
reaction in balance. The altered set-point of the HPA axis hormones observed in stress-
related diseases goes along with an altered reactivity of the HPA axis, and is interpreted as
the body’s inability to adequately terminate stress response, which increases the risk for
disease development [55]. The corticosteroid receptor hypothesis stipulates that
malfunctioning of GR is causal for the inappropriate reaction of the HPA axis to stress [56].
Thus, researchers explored the molecular mechanisms that operate to calibrate GR activity,
with the aim to better understand stress-related diseases.
The discovery of divergent actions of FKBP51 and FKBP52 on GR [5, 20] along with the
correlation of FKBP51 with altered set-points of the HPA axis in squirrel monkeys spurred
their inclusion as candidates in an association study in major depression [57]. This study was
the first to identify a correlation of FKBP51 gene variants with response to antidepressant
treatment, and also with the reactivity of the HPA axis in the dexamethasone (DEX)-CRH
test. FKBP51 genetic polymorphisms and their relationship to antidepressant responses were
confirmed in several large and small patient samples [58–61]. An association of FKBP51
genotype with depression disease status was also discovered, and in one study, it revealed a
gender-specific effect of this association [60, 62–64]. In addition, FKBP51 polymorphisms
were linked to suicide in several samples [63, 65–67] and a gender-specific FKBP51
genotype association with the personality traits of harm avoidance and cooperativeness has
also been reported [68]. Moreover, polymorphisms of FKBP51 influenced recovery from
psychosocial stress in healthy individuals [69].
FKBP51 gene variants are also associated with peritraumatic dissociation [70], an
established risk factor for the development of posttraumatic stress disorder (PTSD) [71].
Several studies link FKBP51 to PTSD and FKBP51 was found to be less expressed in
PTSD, consistent with the observation of enhanced GR responsiveness [72]. Intriguingly,
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recent studies suggested that FKBP51 polymorphisms modify the effects of early life trauma
in PTSD [73–75] and major depression [76].
The reports on FKBP51 and PTSD in particular suggest a function of FKBP51 as a
modulator of the response to stressful life events and as a mediator of gene-environment
interactions. Thus, the risk of disease development critically depends on the FKBP51 gene
status. Even though it is very likely that FKBP51 operates in stress physiology through its
action in GR and the HPA axis function, the exact mechanism of the gene environment
interaction remains to be elucidated, and no associating polymorphism has been reported so
far. However, a recent study reported decreased DNA methylation and increased expression
of FKBP51 in mice after chronic exposure to corticosterone [77]. Thus, it is possible that
FKBP51 gene expression is programmed by stressful life events in a genotype-dependent
fashion, and results of research on this are eagerly awaited.
Immune Function
Several studies report a role of FKBP51 in immune-related diseases and inflammation.
Expression of FKBP51 was enhanced in bone marrow cells from patients suffering from
rheumatoid arthritis [78]. Evidence has also been provided for a modulation of NF-kB-
dependent gene expression by FKBP51, with possible implications for various pathways
[79, 80]. This possibly links FKBP51 to NF-kB and its regulation in cell proliferation and
survival, inflammation, immune regulation, metabolic diseases and hematopoiesis [81, 82].
Another study found FKBP51 and NF-kB up-regulated in bone marrow-derived
mononuclear cells from patients with rheumatoid arthritis [83]. Treatment of chronic
obstructive pulmonary disease goes along with increased expression of FKBP51 [84].
FKBP51 has also been reported to mediate the effect of the immunosuppressant FK506 in
inhibiting endogenous MHC class II-restricted antigen presentation [85]. Since GR is an
established modulator of immune function, FKBP51 mediated regulation of GR activity per
se could provide the basis for a role of FKBP51 in immune processes. Additional FKBP51
effects, such as its impact on NF-kB, are also operative. Mechanistically, evidence from
glioma cells suggests that FKBP51 impacts on the stability of IkB and on phosphorylation of
NF-kB, and enhances DNA binding of NF-kB [79].
FKBP51 is also able to mediate the inhibition of the phosphatase calcineurin, which
activates Nuclear Factor of Activated T cells, by FK506 [86, 87]. This function, however, is
not unique to FKBP51, as the smaller FKBPs also mediate this effect, some of them even
more efficiently [87]. Moreover, FKBP51 has been reported, by some, to interact with
calcineurin in the absence of FK506 [88], but not by others [87].
Concluding Remarks
It is becoming increasingly clear that FKBP52 associates with SHR-chaperone complexes to
regulate hormone binding and continues to play a critical role in receptor translocation to the
nucleus, possibly even regulating the receptors in the nucleus. Although, FKBP51 is
generally considered as a negative regulator of receptor function, evidence suggests that it
displays tissue and/or cell type specific effects on receptor signaling. As a result, both
FKBP51 and FKBP52 are implicated in a variety of diseases, and could serve as therapeutic
targets for the treatment of these diseases. Efforts to therapeutically target the FKBP
proteins are currently underway and these efforts would be enhanced by studies aimed at
improving our understanding of FKBP interactions within the receptor-chaperone complex
both in the cytoplasm and nucleus.
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Box 1. FKBP52: A diverse regulator of steroid hormone receptor signaling
Studies aimed at characterizing FKBP52 as a regulator of receptor maturation and
hormone binding and those characterizing FKBP52 as a regulator of receptor subcellular
localization, have traditionally progressed independent of each other. This review
presents both ideas with equal coverage and, based on the evidence, it is likely that
FKBP52 is a regulator of both receptor hormone binding and receptor localization. The
only area in which the two models do not agree is the timing by which FKBP52
associates with the receptor-chaperone complex and whether or not FKBP51 has a direct
role in this process. When hormone is added to in vitro PR complexes with chemically-
suspended Hsp90 dissociation ability, FKBP51 quickly dissociates, yet FKBP52 remains
bound [89, 90]. Secondly, in an in vivo study in which the Hsp90 complex was suspended
on ice to decrease Hsp90’s dissociation rate, addition of hormone caused FKBP51 to be
replaced with FKBP52 in complexes with GR [19]. Thus, evidence exists to support the
hormone-induced switching of FKBP51 for FKBP52, as depicted in Figure 3. However,
the fact that FKBP52 promotes increased receptor hormone binding affinity [9] suggests
that FKBP52 is present in receptor-chaperone complexes prior to hormone binding and
somehow primes the receptor for hormone binding. Indeed, complexes containing
FKBP52 in the absence of hormone are observed. The FKBP52 FK1 domain is important
for receptor regulation and recent studies suggest that the FK1 domain serves as an
interaction surface that may directly contact the receptor LBD within the complex, to
promote increased hormone binding, as depicted in Figure 2 [9]. Recent evidence
suggests the simultaneous binding of multiple TPR proteins to Hsp90, although these
studies were performed in the absence of Hsp90 client protein [91, 92]. Thus, the
mutually exclusive model for TPR proteins may be more complicated than is currently
thought. It is also important to point out that most studies have been performed using
purified proteins, in the absence of receptor, and, more importantly, in different cell
types. These differences in experimental conditions and systems could at least partially
account for the differences discussed above. It is likely that FKBP52 plays an important
role in the hormone binding step and continues to be critical for receptor localization,
possibly even playing a role in receptor regulation in the nucleus. Further studies are
needed to resolve these discrepancies and to bring these two models together.
Box 2. Role for the FKBPs in protein folding and aggregation disorders
A novel role for Hsp90 and associated cochaperones in protein folding and aggregation
disorders such as Alzheimer’s has emerged in recent years. Modulating Hsp90 directly
may be clinically relevant for protein folding and aggregation disorders [93–96]. Hsp90
cooperates with many cochaperones to act on specific protein subclasses, such as
transmembrane receptors or tau and other disordered proteins. Recent data suggest that
one or more of these cochaperones could be more specific drug targets with fewer
adverse consequences [39, 93]. For example, in a Caenorhabditis elegans model of
tauopathy, tau levels increased and the pathological phenotype worsened when the
ubiquitin ligase CHIP, which is also an Hsp90 cochaperone, and FKBP52 were silenced
[97]. However, the involvement of FKBP51 in tau pathogenesis was not described in this
study, since C. elegans lacks an FKBP51 gene. Recently, FKBP51 was shown to
preserve tau levels, but reduce its phosphorylation, perhaps by cooperating with a set of
phosphatases [39]. FKBP51 also interacts with tau in human Alzheimer’s disease brain
tissue. More recently, increased levels of FKBP52 were shown to correspond with
decreased tau stability [38, 98]. Thus, these two proteins may have opposing roles for tau,
despite similar structural features.
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The roles of the PPIase activity of both FKBP51 and FKBP52 could be critical for the
regulation of intrinsically disordered proteins like tau, since a high percentage of proline
residues is common among this family:[99]. More than 20% of the residues between I151
and Q244 of tau are proline. Most of the known functions of tau are mediated through
MT binding domains distal to this proline-rich region. However many disease-associated
phosphorylation events that seed tau tangle formation occur at proline-directed serine (S)
and threonine (T) residues in this proline-rich region. This strongly suggests that
important structural changes in the proline rich region of tau are regulating tangle
formation. In particular, cis-trans isomerization around these prolines modulates protein
phosphatase binding and activity at specific S/T sites. It is well established that peptidyl-
prolyl isomerase 1 (Pin1) regulates tau phosphorylation in concert with protein
phosphatase 2A (PP2A), specifically at T231 and T212 [100]. FKBP51 and FKBP52
likely have a similar activity; however, unlike Pin1, the FKBPs likely coordinate with
Hsp90 to isomerize tau [50]. Thus, FKBP51 and FKBP52 may improve our
understanding of tau biology and may be targets for drug development efforts in
tauopathies.
Box 3. Open questions for future investigation
• Do the FKBPs interact directly with the receptors within the Hsp90 chaperone
complex in the cytoplasm or do they influence the receptors indirectly through
binding Hsp90?
• What are the FKBP interaction and/or regulatory sites on the receptors? Studies
suggest FKBP52 regulation is localized to the receptor LBD, but can this be
narrowed to a specific surface and or surface residues within the LBD?
• The exchange of FKBP51 for FKBP52 upon hormone binding is not entirely
due to conformational changes in the receptor-chaperone complex, as FKBP52
can be found in association with the complex prior to hormone binding. What
facilitates this exchange and what role does this exchange play in the receptor
signaling pathways given that FKBP52 can still regulate receptor in
experimental systems where FKBP51 is absent?
• Can the FKBPs interact directly with the receptors in an Hsp90-independent
manner in the nucleus and, thus, have Hsp90-independent functional roles in the
receptor signaling pathways?
• Why do the 52KO mice develop normal testis despite significant developmental
defects in other androgen-dependent tissues?
• The embryonic lethality phenotype in the double 51/52KO mice has not been
characterized. At what stage do the embryos die and what causes this lethality?
• What is unique within prostate cancer cells, which allows FKBP51 to act as a
positive regulator of androgen receptor signaling? In line with this question,
evidence suggests a more cell and/or tissue specific role for FKBP51. Within
what cell and or tissue types and under what conditions can FKBP51 act in
addition to prostate cancer cells?
• What is the functional single nucleotide polymorphism of FKBP51 in stress-
related disease and what is the mechanism by which it contributes to the disease
state?
• Is FKBP51 gene expression programmed (permanently altered) by stressful life
experiences?
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• What is the role of Hsp90 in FKBP regulation of tau pathogenesis and what
phosphatases and kinases are involved?
• Can FKBP-specific drugs be designed that distinguish between FKBP51 and
FKBP52?
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Glossary of Terms
Akt Akt is a serine/threonine protein kinase that regulates apoptosis, cell
migration, transcription, proliferation, and glucose metabolism.
Antineoplastic
therapy
Chemotherapy that targets all actively dividing cells.
β importin During nuclear import, β importin tethers incoming proteins to the
nuclear pore complex.
FKBP51 51kDa FK506 binding protein that binds the immunosuppressive
drug FK506 without initiating immunosuppression.
FKBP52 52kDa FK506 binding protein that binds the immunosppressive drug
FK506 without initiating immunosuppression.
FK1 Domain FKBP12-like domain 1 of FKBP51 and FKPB52, responsible for
binding to FK506, for PPIase activity, and for steroid hormone
receptor regulation.
FK2 Domain FKBP12-like domain 2, present in FKBP51 and FKBP52, which
differs slightly from the FK1 and lacks PPIase and FK506 binding
ability.
FK506 Also called tacrolimus, is a macrolide drug that complexes with
FKBP12 and inhibits calcineurin phosphatase activity. This leads to
immunosuppression by blocking T cell signal transduction cascades
and Interleukin-2 transcription.
Geldanamycin This benzoquinone ansamycin antibiotic directly binds Hsp90 and
inhibits its function.
Hsp90 The 90 kDa heat shock protein is a molecular chaperone involved in
protein folding, tumor repression, and cell signaling. Steroid
hormone receptors require association with Hsp90 to fold to a
conformation capable of binding ligand.
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Hypothalamus
pituitary adrenal
(HPA) Axis
Interactions between the hypothalamus, the pituitary gland, and the
adrenal glands are critical parts of the neuroendocrine system. This
pathway is responsible for the regulation of stress reactions, energy
storage and output, emotion and affect, sexuality, digestion, and the
immune system.
MHC II Major Histocompatibility Complex Class II molecules are located on
subclasses of antigen presenting cells and display extracellular
protein fragments to CD4+ helper T-cells to determine the immune
response.
NFκB Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells is
a transcription factor complex found in most animal cells that
regulates cellular responses to infections and stress.
Nup62 Nucleoporin 62 is a complex of proteins which associates with the
importin αβ complex of the nuclear pore to assist in the import of
proteins with nuclear localization signals.
PPIase activity Peptidyl Prolyl Isomerase activity catalyzes cis-trans isomeration
reactions of peptide bonds involving the amino acid proline. PPIase
activity is required for the proper folding of several, but not all,
proteins.
Protein
aggregation
disorders
The agglomeration of proteins occurs in diseases such as
Alzheimer's, Mad Cow, and Huntington's diseases.
Radicicol Also known as monorden, radicicol is a macrolactone antibiotic that
binds Hsp90 and alters its function. It also inhibits tyrosine kinase
and is anti-angiogenic.
Reticulosyte
lysate assembly
system
This cell free assembly system contains all necessary eukaryotic
cofactors for steroid hormone receptor folding and allows for the
reconstitution of the receptors with chaperone complexes in vitro.
Tau Tau proteins are found primarily in neurons of the Central Nervous
System and normally help in microtubule stabilization. Defective
folding of tau and resultant agglomeration is associated with
neurodegenerative diseases such as Alzheimer’s and Parkinson’s
Diseases.
TPR Domain The tetratricopeptide repeat is a structural motif utilized in protein-
protein interactions. The TPR domains on FKBP51 and FKBP52
bind specifically to the extreme C-terminus of Hsp90.
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Figure 1.
FKBP51 and FKBP52 X-ray crystallographic structures. The three-dimensional structure of
human FKBP51 (protein databank number 1KT0) and a composite of two partial structures
for human FKBP52 (protein databank numbers 1Q1C and 1P5Q) are shown in ribbon format
colored based on secondary structure. The important functional domains and regions are
illustrated. The C-terminal TPR domain mediates binding to Hsp90. The FKBP12-like
domains 1 and 2 are also shown. FK2 is similar to FK1 but lacks PPIase activity and does
not bind the immunosuppressive ligand FK506. The FK1 domain both contains a functional
PPIase active site and binds FK506. Although the PPIase activity is not required for receptor
regulation, the FK1 domain is critical for FKBP function. In particular the proline-rich loop
overhanging the PPIase pocket is critical for receptor regulation, is largely responsible for
the divergent functions of FKBP51 and FKBP52, and may serve as a functionally important
interaction surface. The figure was created, including overlaying the two partial FKBP52
structures, using UCSF Chimera version 1.5.
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Figure 2.
Model for FKBP regulation of receptor maturation and hormone binding. The FK1 domain,
the proline-rich loop in particular, is responsible for the divergent functions of the FKBPs
and likely serves as an interaction surface. The difference in the shape of the FKBP FK1
domains shown here illustrates the structural differences in the proline-rich loop between
these two proteins. The current model holds that the association of the FKBPs with the
closed state of the Hsp90 dimer, which is stabilized by the p23 cochaperone, brings the FK1
domain into contact with the receptor LBD to directly influence hormone binding affinity.
As a result of the differences in the FK1 domain, hormone binding is repressed in the
presence of FKBP51 and potentiated in the presence of FKBP52.
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Figure 3.
Models for steroid hormone receptor translocation. According to the classic model (dashed
lines) the chaperone complex dissociates in the cytoplasm from the steroid receptor (SR)
upon hormone (H) binding. This transformed receptor passes through the nuclear pore
complex (NPC) to reach its nuclear sites of action. The novel model is depicted with
continuous lines. Upon steroid binding, the SR heterocomplex exchanges FKBP51 (brown
crescent) for FKBP52 (dashed crescent), which is able to interact with dynein (black). The
chaperone complex serves as a traction chain for the receptor whose retrotransport occurs on
cytoskeletal tracts. The nuclear localization signal (NL1; pink) protrudes upon steroid
binding and the whole SR-chaperone complex translocates through the NPC. The
heterocomplex interacts with structural proteins of the pore, which are also chaperoned.
Receptor transformation is nucleoplasmic and facilitates the binding of the steroid-activated
receptor with promoter sites.
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Figure 4.
FKBP51 is linked to the HPA axis. Upon perception of stress, CRH is released from the
hypothlamus, which promotes synthesis and release of ACTH from the pituitary. ACTH in
turn increases release of cortisol from the adrenal glands. The inhibitory action of cortisol-
activated GR on CRH and ACTH terminates the hormonal stress response and keeps the
HPA axis in balance. FKBP51 expression is increased by GR, and acts back on GR in an
inhibitory manner. This ultrashort feedback loop provides a mechanism by which FKBP51
regulates HPA axis activity, affects the impact of cortisol in target tissues, and links stress to
its other molecular and physiological functions.
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